Cnidium

Other Names

Cicuta monnieri (L.) CrantzCnidii FructusCnidii Monnieri FructusCnidii RhizomaCnidium fruitCnidium monnieri (L.) CussonCnidium monnieri (L.) Spreng.Cnidium monnieri var. formosanum (Y.Yabe) Kitag.Cnidium monnieri var. monnieriCnidium seedDiscopleura daucifolia (Buch.-Ham.) Benth. & Hook.f.Fructus CnidiiJashoshiLigusticum monnieri (L.) Calest.Monnier's CnidiumMonnier's snowparsleyPinasgelon monnieri (L.) Raf.SasangiaSelinum densiflorum Salisb.Selinum monnieri L.She ChuangShe Chuang DzeShe Chuang ZiShechuangziXa sang tuXasangtu蛇床子

Synopsis

Cnidium (Cnidium monnieri (L.) Cusson): A Comprehensive Reference

1. Identity and Botanical Description

Botanical name: Cnidium monnieri (L.) Cuss., a species in the genus Cnidium which contains approximately 11 to 35 species and belongs to the family Apiaceae (carrot family). The plant was reclassified by Pierre Cusson into today's valid botanical systematics in 1787.

Common and regional names: Its pharmaceutical name, English name, and Chinese Pinyin name are Cnidii Fructus, "Cnidium seed," and "She Chuang Zi" respectively. As the herb is widely grown in China, Japan, Korea, and Vietnam, it is also known as "Jashoshi" in Japanese, "Sasangia" in Korean, and "Xa sang tu" in Vietnamese. In English, the plant is sometimes called Monnier's Snowparsley.

Morphology: Plants are annual, growing 10–60 (–80) cm. The taproot is 2–3 mm thick. The stem is solitary, striate, and scabrous. Lower petioles are 3–8 cm, with an ovate-lanceolate blade 3–8 × 2–5 cm, 2–3-pinnate, with ultimate segments linear to linear-lanceolate, 3–10 × 1–1.5 mm.

Geographic distribution: The plant grows in most parts of mainland China and is also found in Russia, Korea, Vietnam, North America, and some European countries. Within China, the main growing provinces are Hebei, Jiangsu, Zhejiang, Shandong, and Sichuan.

Medicinal part: The medicinal substance used is the dry fruit of the plant Cnidium monnieri (L.) from the Apiaceae family. It is usually harvested in summer and autumn when the fruits are ripe.

Regulatory status: Cnidium monnieri is officially recognized in the Chinese Pharmacopoeia as a traditional herbal medicine, listed under the name "She Chuang Zi." In the United States, the FDA classifies Cnidium monnieri as a dietary supplement ingredient rather than an approved drug, with new dietary ingredient notifications submitted in 2004 confirming its inclusion in multi-ingredient formulations. Quality control measures for Cnidium monnieri emphasize standardization of bioactive coumarins, particularly osthole, as specified in pharmacopoeial monographs to verify potency and purity.

Common forms and preparations: Cnidium monnieri is available in extracts, powders, and topical ointments. Oral dosages vary significantly; traditional recommendations range from 6–15 grams daily for raw material or 100–200 mg daily for standardized extracts. The whole dried fruit may also be prepared as a decoction for internal or external use.

2. Traditional and Historical Use

The first record of Cnidium monnieri (Cnidii Fructus) is found in Shennong's Classic of Materia Medica (Shen Nong Ben Cao Jing). As for its properties, it is described as acrid, bitter, warm, and slightly toxic. It was recognized as a "top-quality" herb in that foundational document.

Records dating to 390–278 BC note that Cnidium monnieri was among the first plants recorded as medicines, appearing in the Chinese literary work "Sorrow after Departure." Cnidium monnieri has been one of the most widely used traditional herbal medicines, with its fruits used to treat a variety of diseases in China, Vietnam, and Japan.

In the framework of Traditional Chinese Medicine (TCM), She Chuang Zi is considered to warm the kidneys, strengthen yang, reduce dampness, and dispel wind — meaning it can replenish yang qi in the kidneys and remove dampness and wind pathogenic qi that causes diseases in the human body.

Indications in traditional use: Main traditional uses and indications include impotence; wet, itchy, and clammy scrotum; womb-cold-induced sterility in females; cold-damp-induced morbid leukorrhea; itchy, sore, swollen vagina; arthralgia due to wind and dampness; scabies; and eczema.

The Qing Dynasty physician Chen Shi-duo commented in his work Ben Cao Xin Bian (New Chapters on Materia Medica) that "Cnidium seeds have amazing healing properties for both external and internal treatments."

Classical formulas: One classical multi-herb formula, Zan Yu Dan from Jing Yue Quan Shu (Jingyue's Complete Works), was formulated with Dang Gui, Gou Qi Zi, Yin Yang Huo, and Rou Cong Rong among others, to treat impotence due to kidney deficiency and infertility caused by cold uterus.

Traditional dosage form (decoction): Recommended traditional dosage in decoction is 3 to 9 grams.

Cnidii Fructus has also been used historically in the treatment of lumbar pain. The fruit is known for its anti-inflammatory and analgesic properties, which can help alleviate discomfort in the lower back. Traditional preparations often involve combining Cnidii Fructus with other herbs to enhance its therapeutic effects.

3. Key Constituents and Active Compounds

3.1 Overview of Phytochemistry

A total of 429 chemical constituents have been elucidated from Cnidium monnieri, which can be categorized as coumarins, volatile constituents, liposoluble compounds, chromones, monoterpenoid glucosides, terpenoids, glycosides, glucides, and other compounds.

3.2 Coumarins (Primary Class)

To date, 350 compounds have been isolated and identified from Cnidium monnieri, including the main active constituent, coumarins. The main active components in C. monnieri are coumarins (mainly osthole) and volatile compounds, exhibiting multiple pharmacological effects, including anti-inflammatory, antibacterial, antioxidant, anti-tumor, and immune-regulating effects.

The identified key coumarins include osthole, imperatorin, bergapten, isopimpinellin, xanthotoxol, xanthotoxin, cnidimonal, cnidimarin, and numerous glucosides. Additional coumarins catalogued from the plant include bergapten (5-methoxypsoralen), columbianadin, isoimperatorin, isoporalen, psoralen, scoparone, archangelicin, and many others.

Osthole (osthol): Osthole is chemically designated as 7-methoxy-8-(3-methyl-2-butenyl)-2H-1-benzopyran-2-one, a natural product found in several medicinal plants including Cnidium monnieri and Angelica pubescens. Osthole is the main active ingredient of the traditional herbal medicine Cnidium monnieri (L.) Cuss., with molecular formula C₁₅H₁₆O₃ and molecular weight 244.29.

3.3 Chromones

Chromones are a family of compounds with multiple biological activities including antitumor, antimicrobial, antiviral, anti-inflammatory, and antioxidant effects. Isolated chromone compounds from Cnidium monnieri include cnidimol B, peucenin, 5,7-dihydroxychromone, 5-O-methylvisamminol, hamaudol, cimifugin, oroselone, cnidimol A, and a range of monnieriside compounds (monnierside A through G), among others.

3.4 Volatile Compounds

Volatile constituents identified from C. monnieri include bornyl isovalerate, alpha-pinene, isoborneol, cnidiline, cnidimine (edultin), isopimpinellin, columbianadin, and sesquiterpenes.

3.5 Furanocoumarins

The fruit also contains furanocoumarins such as bergapten and xanthotoxin. Xanthotoxin as a common methoxylated furanocoumarin has been reported to inhibit the human fungi Candida albicans and Cryptococcus laurentii. These furanocoumarins are toxicologically relevant due to their photosensitizing potential (see Safety section).

4. Established Mechanisms of Action

4.1 cAMP and cGMP Modulation

The mechanisms of multiple pharmacological activities of osthole are very likely related to its modulatory effect on cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels, though some mechanisms remain unclear.

4.2 Sexual Function / Vasodilation

Available aphrodisiacs improve sexual performance or penile arousal by modulating blood flow to the penile veins through nitric oxide signaling and the phosphodiesterase-5 (PDE5) inhibitory pathway. Computational and in vitro studies indicate that compounds from Cnidium monnieri may act through this pathway. The main active compounds of C. monnieri, imperatorin (3–300 µM) and osthole (1–100 µM), showed a concentration-dependent vasorelaxation effect, with half-maximal effective concentration values of 9.14 ± 0.06 and 5.98 ± 0.06 µM, respectively, in preclinical models. Moreover, osthole and imperatorin relaxed constricted rat aortic rings via inhibition of the Ca²⁺ channel in a dose-dependent manner.

4.3 Bone Metabolism

Mechanistically, osthole promotes osteogenic differentiation by activating the Wnt/β-catenin and BMP-2/Smad1/5/8 signaling pathways and suppresses RANKL-induced osteoclastogenesis and osteoclast activity. Studies have shown that osthole stimulates the expression of osteoprotegerin (OPG) via activation of β-catenin signaling, thereby downregulating osteoclastogenesis.

4.4 Anti-inflammatory Pathways

The in vitro and in vivo anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri, occurs via the blocking of the activation of the NF-κB and MAPK/p38 pathways. Multiple coumarin isolates from C. monnieri fruits exhibit inhibition of superoxide anion generation by human neutrophils and inhibit elastase release in inflammatory assays.

4.5 Anticancer Mechanisms

Studies have elucidated that the anticancer mechanism of action of osthole mainly involves inhibiting cancer cell proliferation, inducing cancer cell apoptosis, inhibiting invasion and migration of cancer cells, inhibiting cancer angiogenesis, increasing sensitivity to chemotherapy drugs, and reversing multidrug resistance of cancer cells.

4.6 Neuroprotective Mechanisms

Preclinical review evidence indicates that C. monnieri compounds act through mechanisms including COX-2 and iNOS inhibition, TRPV1 and p-ERK downregulation, and modulation of calcium signaling pathways (e.g., IP3R/SOCE). Osthole (at 12.5 mg/kg and 25 mg/kg in animal models) has been found to regulate the expression of apoptosis-related proteins Bcl-2 and Bax in the hippocampus of Alzheimer's disease model rats, increasing the ratio of Bcl-2/Bax and exerting anti-apoptotic and protective effects on hippocampal neurons.

4.7 Glutamate Release and Neuronal Activity

Studies examined the effects of osthole and imperatorin on the release of glutamate from rat hippocampal synaptosomes. Results showed that osthole or imperatorin significantly facilitated glutamate release in a concentration-dependent manner, and this facilitatory action was blocked by a vesicular transporter inhibitor, indicating that release facilitation results from enhancement of vesicular exocytosis. The facilitation of glutamate release could be attributed to an increase in voltage-dependent Ca²⁺ influx.

5. Scientific Evidence by Area of Use

5.1 Sexual Function and Erectile Dysfunction

Evidence type: predominantly preclinical (in vitro and animal); limited clinical evidence.

A pro-erectile herb from traditional Chinese medicine, Cnidium monnieri and its main bioactive compound osthole appear to have mechanisms similar to Viagra in penile tissue and the hippocampus; however, the influence of Cnidium monnieri on testosterone and cognition remains unexplored.

Research has investigated the inhibitory potential of bioactive compounds from C. monnieri against phosphodiesterase-5 as a target for erectile dysfunction using computational approaches. Preclinical vasorelaxation studies demonstrated that orally administered Cnidium monnieri extract significantly reduced the blood pressure of spontaneously hypertensive rats, and the research characterizes it as a promising treatment option for hypertension, though further studies are required.

At the clinical level, Cnidium monnieri fruit (Cnidii Fructus) has been studied as part of compound formulations. Compound Xuanju Capsule (CXC) — composed of Black Ant, Epimedii folium, Lycii Fructus, and Cnidii Fructus — was the subject of a meta-analysis showing that compared with PDE5 inhibitor alone, CXC combined with PDE5 inhibitors significantly improved IIEF-5 scores by 3.19, clinical effectiveness rate by 23%, penile cavernous blood flow by 5.21 cm/s, and serum testosterone levels by 4.09 nmol/L. Limitation: This meta-analysis examined a multi-ingredient formula, making it impossible to attribute any effects specifically to Cnidium monnieri in isolation. No large, placebo-controlled trials of cnidium as a stand-alone intervention for erectile dysfunction in humans have been reported in the peer-reviewed literature.

5.2 Bone Health and Osteoporosis

Evidence type: in vitro and animal (rodent) models; no adequate human clinical trials.

Experiments conducted in vitro and in vivo have shown that osthole inhibits bone resorption, promotes bone formation, and increases bone mass. More specifically, osthole increases osteoblast-related bone formation and decreases osteoclast-related bone resorption, suppressing osteoporosis-related fragility fracture in preclinical models.

Osthole has demonstrated an estrogenic effect in preventing bone loss in ovariectomized rats — a standard preclinical model for postmenopausal osteoporosis. Osthole promoted bone marrow stromal stem cell differentiation toward osteogenesis at a dosage of 1 × 10⁻⁵ mol/L and also increased the gene expression of bFGF, OSX, Runx2, and IGF-1. At a concentration of 1 × 10⁻⁵ mol/L, osthole could stimulate differentiation and maturation of rat calvarial osteoblasts and exert no cytotoxic effect in vitro.

Osthole is a coumarin derivative extracted from Cnidium monnieri and Angelica pubescens; it has been reported to have osteogenic and anti-osteoporotic properties, though the underlying mechanism of its benefit has not been fully clarified. More studies should be performed due, at least in part, to the uncertainty of drug targets, and further pharmacological investigation of osthole in osteoporosis treatment might lead to the development of potential drug candidates.

Osthole has poor water solubility, low bioavailability, and poor infiltration for bone tissue; researchers have therefore explored using a water-soluble chitosan derivative as a carrier to boost efficacy.

5.3 Dermatological Conditions (Antipruritic, Antifungal, Antibacterial)

Evidence type: in vitro and limited preclinical in vivo; some topical use supported by traditional practice.

Cnidium monnieri is renowned for its broad range of pharmaceutical properties, particularly in treating female genitals, male impotence, frigidity, and skin diseases, as well as exerting antipruritic, anti-allergic, antidermatophytic, antibacterial, antifungal, and anti-osteoporotic effects.

From in vitro studies, Cnidium monnieri inhibited intestinal Candida species including C. albicans, C. krusei, and C. tropicalis at an average minimum inhibitory concentration of 12.5 g/L. Osthole (at 4–16 µg/mL) demonstrated a remarkable synergistic effect with fluconazole against fluconazole-resistant C. albicans, with the possible mechanism related to endogenous reactive oxygen species augmentation.

Multiple coumarin isolates from C. monnieri fruits exhibit inhibition of superoxide anion generation by human neutrophils and inhibition of elastase release with IC₅₀ values ≤ 7.83 µg/mL in vitro. Bioactive isolates were identified as potential candidates for the treatment or prevention of various inflammatory diseases.

Overall assessment: The antimicrobial and antipruritic effects are well-characterized in vitro and are consistent with centuries of topical use. Robust, controlled clinical trial evidence in humans is lacking.

5.4 Anticancer Activity

Evidence type: primarily in vitro (cell lines) and some animal models; no clinical trials in humans.

Osthole, a coumarin compound extracted from Cnidium monnieri, has become a research hotspot for anticancer effects. Studies have elucidated that its underlying mechanism of action mainly involves inhibiting cancer cell proliferation, inducing apoptosis, inhibiting invasion and migration, inhibiting angiogenesis, increasing sensitivity to chemotherapy drugs, and reversing multidrug resistance.

In vitro studies have reported cytotoxic activity of coumarins from Cnidium monnieri fruits against leukemia cell lines. Xanthotoxol, a bioactive furocoumarin from Fructus Cnidii and Cnidium monnieri, exhibits various pharmacological activities including anticancer effects; findings reveal that it has significant anticancer activity against lung, skin, blood, and thyroid cancers in cell-line models. Evidence strength: All reported anticancer data derive from preclinical studies. No clinical evidence supports the use of Cnidium monnieri or its isolated compounds as a cancer treatment in humans.

5.5 Neuroprotection and Cognitive Function

Evidence type: animal and in vitro models only.

Chronic neurodegenerative diseases such as Alzheimer's and Parkinson's are primarily driven by oxidative stress, neuroinflammation, mitochondrial dysfunction, and calcium dyshomeostasis. Review evidence highlights the compound-specific and multi-target effects of C. monnieri in preclinical models of Alzheimer's disease, depression, and neuropathic pain.

In terms of neuronal ultrastructure injury alleviation, osthole displayed an effect similar to donepezil, the first-line medication for Alzheimer's disease management, in animal studies. The extract demonstrates promising antidepressant effects by restoring monoaminergic neurotransmission and exerting anti-inflammatory effects in key brain regions in preclinical models.

Research investigated the protective effects of osthole on MPP+-induced cytotoxicity in cultured rat adrenal pheochromocytoma (PC12) cells; pretreatment with osthole on PC12 cells significantly reduced the loss of cell viability, the release of lactate dehydrogenase, and the activity of caspase-3 and cytochrome c. Evidence strength: All neuroprotective data originate from animal and cell-culture models. No human clinical trials have evaluated Cnidium monnieri for cognitive or neuroprotective outcomes.

5.6 Cardiovascular Effects

Evidence type: in vitro and animal studies; no human clinical trials.

In preclinical studies, imperatorin (3–300 µM) and osthole (1–100 µM) showed concentration-dependent vasorelaxation effects. Orally administered Cnidium monnieri extract significantly reduced the blood pressure of spontaneously hypertensive rats. Additionally, imperatorin inhibited cardiac myocyte hypertrophy, which could potentially attenuate hypertension, myocardial hypertrophy, and cardiac fibrosis. No controlled human studies are available.

5.7 Anti-inflammatory and Analgesic Effects

Evidence type: in vitro and preclinical animal models.

In terms of pharmacological effects, coumarins from C. monnieri possess anti-hypertensive, anti-inflammatory, analgesic, and anticancer effects. The primary documented mechanism is inhibition of NF-κB and MAPK/p38 pathways by osthole, as described above. No large-scale human trials exist.

5.8 Sedative/Hypnotic Activity

Evidence type: animal studies only.

In animal models, the hypnotic active component of Cnidium monnieri (130–520 mg/kg) exerted a hypnotic effect but had no influence on the animals' learning and memory functions. The herb's incubation period was not significantly different from that of diazepam, and it could induce sleep rapidly and significantly prolong duration, with hangover response and tolerance reported as weaker than those of diazepam. Evidence strength: Preclinical only; these findings cannot be extrapolated to human use without clinical data.

6. Body Systems and Health Areas Associated with Cnidium monnieri

Reproductive system: Male erectile function, libido, and female reproductive health (anti-leukorrheal, antipruritic effects on vulva and vagina) — both traditional use and preliminary preclinical evidence.
Musculoskeletal system: Bone metabolism, osteoporosis prevention — extensive preclinical evidence (in vitro and animal); no human clinical trials.
Integumentary system (skin): Antipruritic, antifungal, antibacterial, and anti-allergic effects for skin conditions including eczema and dermatophytosis — in vitro and traditional topical use.
Central nervous system: Neuroprotection, possible cognitive support, sedative/hypnotic activity — animal and in vitro models only.
Cardiovascular system: Vasodilation, antihypertensive activity — preclinical models only.
Immune system: Immunomodulatory and anti-inflammatory effects via NF-κB and MAPK/p38 pathway inhibition — preclinical only.
Oncology (preclinical): Cytotoxic activity against multiple cancer cell lines — in vitro data only; no clinical relevance established.

7. Dosage Forms and Reported Dosages

Traditional TCM decoction dosage is recorded as 3 to 9 grams of dried fruit per dose. In modern supplement form, Cnidium monnieri is available as extracts, powders, and topical ointments; oral dosages reported vary from 6–15 grams daily for raw material or 100–200 mg daily for standardized extracts.

In the preclinical bone research literature, osthole doses of 1 × 10⁻⁵ mol/L were used in in vitro studies of osteoblast differentiation; at this concentration it stimulated differentiation and maturation of rat calvarial osteoblasts with no cytotoxic effect. In Alzheimer's disease animal model research, osthole doses of 12.5 mg/kg and 25 mg/kg were administered to rats.

In the subchronic toxicity study of an imperatorin-rich fraction (CMS-1) from Cnidium monnieri, loss of appetite, hypoactivity, and yellow urine were found in medium (300 mg/kg/day) and high (900 mg/kg/day) dose groups of rats after the first oral administration; the high dose group showed a significant decrease in food intake and body weight.

Modern analytical techniques including HPLC, GC-MS, and UPLC-QTOF-MS have enabled more precise detection and quality control of chemical components in C. monnieri.

8. Safety Considerations and Interactions

8.1 Traditional Safety Classification

According to its traditional classification, Cnidium monnieri is described as slightly toxic.

8.2 Photosensitivity

Cnidium contains furocoumarins, which can increase sensitivity to sunlight and raise the risk of sunburn in some cases, particularly when applied topically. The specific furanocoumarins responsible are bergapten and xanthotoxin, both of which are well-characterized photosensitizers. This effect is particularly relevant for topical preparations.

8.3 Gastrointestinal Effects

While used for centuries, Cnidium monnieri's potential side effects include mild gastrointestinal upset, such as a bitter taste in the mouth or stomach discomfort. Photosensitivity, an increased sensitivity to sunlight, has also been reported.

8.4 Subchronic Toxicology Data

Subchronic toxicity of an imperatorin-rich fraction of Cnidium monnieri was studied. The toxicity target organs included the digestive, immune, and cardiovascular systems. Most toxicities were reversible upon discontinuation of treatment. Hair loss was observed in the high and medium dose groups in the study after 2–3 weeks of treatment.

8.5 Pregnancy and Lactation

There is insufficient safety data regarding Cnidium monnieri use during pregnancy or lactation. Traditional texts often advise caution, and modern clinicians generally recommend avoiding it during these periods unless specifically prescribed by an experienced practitioner.

8.6 Pediatric Use

The safety of Cnidium monnieri supplements in children is not well established, and use is not typically recommended unless supervised by a qualified healthcare professional.

8.7 Drug Interactions

Contraindications cited in traditional texts include avoiding use during pregnancy and breastfeeding due to insufficient safety information. People taking specific herbs and medications traditionally considered incompatible, including croton seed, peony root, or fritillaria, are also advised to avoid concurrent use of Cnidium monnieri. The presence of furocoumarins also raises the possibility of cytochrome P450 enzyme interactions, though specific interaction data from controlled studies are limited.

8.8 Research Gaps and Evidence Limitations

Cnidium monnieri has demonstrated impressive potential for the management of various diseases in extensive preclinical research. However, since most studies are overly concentrated on osthole, more research is needed to investigate other chemical constituents. Although osthole and coumarin compounds have been identified as active ingredients responsible for pharmacological effects, the mechanism of action of C. monnieri is still not fully understood. Studies are further needed to analyze structure-activity relationships and to expose the full toxicity and clinical consequences of the plant before it can be established as a pharmaceutical agent.

Pharmacokinetic studies showed osthole uptake and utilization are fast and efficient in the body; however, the mechanisms of multiple pharmacological activities are very likely related to the modulatory effect on cAMP and cGMP levels, though some mechanisms remain unclear.

References

Health Conditions

Health conditions that Cnidium may help support.

Libido & Sexual Vitality (Men's)Traditional
Cnidium (Cnidium monnieri) fruit is used in TCM to enhance male sexual function, treat impotence, and increase libido. Its active compound osthole has demonstrated PDE5-inhibitory and NO-enhancing properties in animal studies, supporting a mechanism similar to Viagra. Human clinical data are limited.

Body Systems

Body systems that Cnidium may help support.

No body systems available.